Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 4/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | NCEH1 | Q6PIU2 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16237325 | 0.93 | MAPT (0.53) | MAPTELANENCEH1LMNA | |
| SCHEMBL5619762 | 0.89 | MAPT (0.46) | MAPTMEN1KMT2ACHEK1ELANE | |
| SCHEMBL16236423 | 0.87 | MAPT (0.65) | MAPTMEN1KMT2AELANENCEH1 | |
| SCHEMBL16236807 | 0.87 | MAPT (0.47) | MAPTELANENCEH1LMNA | |
| Hydrochloric Acid SCHEMBL16236126 | 0.84 | MAPT (0.49) | MAPTCHEK1ELANENCEH1LMNA | |
| SCHEMBL15247643 | 0.84 | PIM1 (0.54) | MAPTMEN1KMT2AALOX5NCEH1 | |
| SCHEMBL16236084 | 0.83 | ELANE (0.49) | MAPTMEN1KMT2AELANE | |
| Hydrochloric Acid SCHEMBL16236748 | 0.82 | MAPT (0.43) | MAPTCHEK1ELANENCEH1LMNA | |
| SCHEMBL16236174 | 0.81 | PTGS2 (0.43) | MAPTKMT2AELANENCEH1LMNA | |
| SCHEMBL16236701 | 0.80 | LMNA (0.63) | MAPTMEN1KMT2ANCEH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997050-B1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA SRL (IT) | 2018-01-17 | — | — | EP | disclosed |
| US-9714303-B2 | Catalyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2017-07-25 | — | — | US | disclosed |
| US-20160115261-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia, s.r.l. (IT) | 2016-04-28 | — | — | US | disclosed |
| EP-2997050-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia S.r.l. (IT) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184171-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
| EP-2803678-A1 | Catalyst components for the polymerization of olefins | Basell Poliolefine Italia S.r.l. (IT) | 2014-11-19 | — | — | EP | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-7164026-B2 | Polymer-carrying optically active binaphthyl type oxazoline compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7164026-B2 | Polymer-carrying optically active binaphthyl type oxazoline compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20040097738-A1 | Polymer-carrying optically active binaphthyl type oxazoline compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | MAPT 4525/4885MEN1 3086/4885KMT2A 3611/4885 |
| US-20040097738-A1 | Polymer-carrying optically active binaphthyl type oxazoline compound | LUC7L2, CNOT7, GRB7 | MAPT 2819/4885MEN1 3587/4885KMT2A 1763/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | MAPT 4525/4885MEN1 3086/4885KMT2A 3611/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | MAPT 4525/4885MEN1 3086/4885KMT2A 3611/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | MAPT 4461/4885MEN1 3270/4885KMT2A 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.